Smartphone language features may help identify adverse post-traumatic neuropsychiatric sequelae and their trajectories
- PMID: 40406207
- PMCID: PMC12092297
- DOI: 10.1038/s44277-025-00028-x
Smartphone language features may help identify adverse post-traumatic neuropsychiatric sequelae and their trajectories
Abstract
Language features may reflect underlying cognitive and emotional processes following a traumatic event that portend clinical outcomes. The authors sought to determine whether language features from usual smartphone use were markers associated with concurrent posttraumatic symptoms and worsening or improving posttraumatic symptoms over time following a traumatic exposure. This investigation was a secondary analysis of the Advancing Understanding of RecOvery afteR traumA study, a longitudinal study of traumatic outcomes among survivors recruited from 33 emergency departments across the United States. Adverse posttraumatic sequelae were assessed over the six months following the initial traumatic exposure. Language features were extracted from usual smartphone use in a specialized app. Bivariate linear mixed models were used to identify and validate language features that are markers associated with posttraumatic symptoms. Participants were 1744 trauma survivors, with a mean age of 39 [SD = 13] years old, and 56% were female. Fourteen language features were associated with severity level of posttraumatic symptoms at specific timepoints (cross-sectional markers) and five features were associated with change in severity level of posttraumatic symptoms (longitudinal markers). References to the body and health or illness were predictive of worsening pain, somatic, and thinking/concentration/fatigue symptom severity over time. An increase in references to others was associated with improvement in somatic symptom severity over time and increases in expressions of causation or cognitive processes were associated with improvement in pain symptom severity over time. Language features derived from usual smartphone use can convey important information about health, functioning, and recovery following a traumatic event. Clinicians might utilize such information to determine who may experience a high symptom burden or risk of worsening posttraumatic symptoms.
Keywords: Diagnostic markers; Neurological manifestations.
Plain language summary
Via usual smartphone use following trauma exposure, this study identified language markers associated with patient-reported severity and change in severity for multiple symptoms. Using language markers as a proxy for the status of and changes in specific symptoms supports efficient remote health status monitoring and can provide clinicians with valuable real-time insights into health, functioning, and recovery. These insights can be leveraged to guide targeted interventions tailored to individual trauma survivors.
© The Author(s) 2025.
Conflict of interest statement
Competing interestsDr. Vizer reports no financial relationships with commercial interests. Dr. Pierce receives support from the National Institute of Mental Health, K01 MH126079. Ms. Ji reports no financial relationships with commercial interests. Dr. Bucher reports no financial relationships with commercial interests. Dr. Liu reports no financial relationships with commercial interests. Dr. Ungar reports no financial relationships with commercial interests. Dr. Giorgi reports no financial relationships with commercial interests. Dr. Xing reports no financial relationships with commercial interests. Dr. House reports no financial relationships with commercial interests. Dr. Beaudoin reports no financial relationships with commercial interests. Dr. Stevens reports no financial relationships with commercial interests. Dr. Neylan has received research support from NIH, VA, and Rainwater Charitable Foundation, and consulting income from Jazz Pharmaceuticals. In the last three years Dr Clifford has received research funding from the NSF, NIH and LifeBell AI, and unrestricted donations from AliveCor Inc, Amazon Research, the Center for Discovery, the Gates Foundation, Google, the Gordon and Betty Moore Foundation, MathWorks, Microsoft Research, Nextsense Inc, One Mind Foundation, and the Rett Research Foundation. Dr Clifford has financial interest in AliveCor Inc and Nextsense Inc. He also is the CTO of MindChild Medical with significant stock. These relationships are unconnected to the current work. Dr. Jovanovic receives support from the National Institute of Mental Health, R01 MH129495. Dr. Linnstaedt reports no financial relationships with commercial interests. Dr. Germine receives funding from the National Institute of Mental Health (R01 MH121617) and is on the board of the Many Brains Project. Her family also has equity in Intelerad Medical Systems, Inc. Dr. Bollen reports no financial relationships with commercial interests. Dr. Rauch reported serving as secretary of the Society of Biological Psychiatry; serving as a board member of Community Psychiatry and Mindpath Health; serving as a board member of National Association of Behavioral Healthcare; serving as secretary and a board member for the Anxiety and Depression Association of America; serving as a board member of the National Network of Depression Centers; receiving royalties from Oxford University Press, American Psychiatric Publishing Inc, and Springer Publishing; and receiving personal fees from the Society of Biological Psychiatry, Community Psychiatry and Mindpath Health, and National Association of Behavioral Healthcare outside the submitted work. Dr. Haran reports no financial relationships with commercial interests. Dr. Storrow reports no financial relationships with commercial interests. Dr. Lewandowski reports no financial relationships with commercial interests. Dr. Musey reports no financial relationships with commercial interests. Dr. Hendry reports no financial relationships with commercial interests. Dr. Sheikh reports no financial relationships with commercial interests. Dr. Jones has no competing interests related to this work, though he has been an investigator on studies funded by AstraZeneca, Vapotherm, Abbott, and Ophirex. Dr. Punches reports no financial relationships with commercial interests. Dr. Hudak reports no financial relationships with commercial interests. Dr. Pascual reports no financial relationships with commercial interests. Dr. Seamon reports no financial relationships with commercial interests. Dr. Harris reports no financial relationships with commercial interests. Dr. Pearson reports no financial relationships with commercial interests. Dr. Peak reports no financial relationships with commercial interests. Dr. Merchant reports no financial relationships with commercial interests. Dr. Domeier reports no financial relationships with commercial interests. Dr. O’Neil reports no financial relationships with commercial interests. Dr. Sergot reports no financial relationships with commercial interests. Dr. Sanchez reports no financial relationships with commercial interests. Dr. Bruce reports no financial relationships with commercial interests. Dr. Harte has no competing interest related to this work, though in the last three years he has received research funding from NIH, Aptinyx, and Arbor Medical Innovations, and consulting payments from Memorial Sloan Kettering Cancer Center, Wayne State University, Indiana University Indianapolis, The Ohio State University, Dana Farber Cancer Institute, and Stanford University. In the past 3 years, Dr. Kessler was a consultant for Cambridge Health Alliance, Canandaigua VA Medical Center, Holmusk, Partners Healthcare, Inc., RallyPoint Networks, Inc., and Sage Therapeutics. He has stock options in Cerebral Inc., Mirah, PYM, and Roga Sciences. Dr. Koenen has been a paid scientific consultant for the US Department of Justice and Covington Burling, LLP over the last three years. She receives royalties from Guilford Press and Oxford University Press. Dr. McLean has served as a consultant for Walter Reed Army Institute for Research, Arbor Medical Innovations, and BioXcel Therapeutics, Inc. Dr. An reports no financial relationships with commercial interests. The remaining authors have nothing to disclose.
Figures
References
-
- Kilpatrick DG, Ruggiero KJ, Acierno R, Saunders BE, Resnick HS, Best CL. Violence and risk of PTSD, major depression, substance abuse/dependence, and comorbidity: results from the national survey of adolescents. J Consult Clin Psychol. 2003;71:692–700. 10.1037/0022-006x.71.4.692. - PubMed
-
- Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–45. 10.1001/archinte.163.20.2433. - PubMed
LinkOut - more resources
Full Text Sources